ST红太阳(000525) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥1,050,375,718.67, a decrease of 44.64% compared to the same period last year[3]. - The net profit attributable to shareholders was ¥5,432,857.82, down 98.35% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was -¥32,253,826.98, representing a decline of 109.04% compared to the previous year[3]. - The basic earnings per share decreased by 98.34% to ¥0.0094[3]. - Total operating revenue for Q3 2023 was ¥2,652,867,931.99, a decrease of 50.7% compared to ¥5,373,920,335.44 in the same period last year[19]. - Net profit for Q3 2023 was ¥15,811,267.65, a significant decline from ¥936,917,951.55 in Q3 2022, representing a decrease of 98.3%[20]. - The total comprehensive income attributable to the parent company for Q3 2023 was CNY 23,454,516.80, a decrease from CNY 945,722,388.51 in the same period last year[21]. - Basic and diluted earnings per share for Q3 2023 were CNY 0.0404, significantly lower than CNY 1.6284 in the same quarter last year[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,243,100,893.31, a slight decrease of 0.37% from the end of the previous year[3]. - The company's total assets as of Q3 2023 amounted to ¥10,243,100,893.31, slightly down from ¥10,280,802,563.89 at the end of the previous quarter[17]. - Current liabilities totaled ¥6,985,193,982.64, an increase from ¥6,886,122,050.54 in the previous quarter, indicating a rise of 1.4%[17]. - Non-current liabilities decreased to ¥1,868,908,109.68 from ¥1,996,385,378.01, reflecting a reduction of 6.4%[17]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥380,688,759.45, down 40.40%[3]. - The net cash flow from operating activities for the current period was CNY 380,688,759.45, down from CNY 638,731,484.58 in the previous year[22]. - Cash inflow from operating activities totaled CNY 2,876,602,770.83, compared to CNY 5,101,223,574.21 in the prior year, indicating a decline of approximately 43.5%[22]. - The total cash outflow from operating activities was CNY 2,495,914,011.38, compared to CNY 4,462,492,089.63 in the previous year, indicating a reduction of approximately 44%[22]. - The company reported a cash flow net increase of CNY -110,581,480.71 for the current period, compared to CNY -1,516,762.17 in the same period last year[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 24.445 million[11]. - The largest shareholder, Nanjing First Pesticide Group Co., Ltd., holds 31.50% of shares, totaling 182,924,731 shares[11]. - The company’s major shareholders have pledged a significant number of shares, with Nanjing First Pesticide Group pledging 167,850,000 shares[11]. - The company’s shareholding structure indicates that Nanjing First Pesticide Group is the controlling shareholder, while Hongtai Group is the second-largest shareholder with a 1.64% stake[11]. Inventory and Receivables - The company reported a significant increase in contract liabilities, which rose by 226.76% to ¥488,766,691.88[6]. - The company's inventory increased by 37.82% to ¥1,541,475,299.90, indicating a buildup of stock[6]. - Accounts receivable increased from 836,274,091.05 CNY at the beginning of the year to 1,051,314,925.54 CNY, representing a growth of about 25.7%[15]. - The company reported a significant increase in other receivables, rising from 1,787,540,328.57 CNY to 1,867,881,282.65 CNY, an increase of approximately 4.9%[15]. Research and Development - Research and development expenses for Q3 2023 were ¥118,563,004.71, down 50.7% from ¥240,343,986.91 in Q3 2022[20]. Regulatory and Compliance - The company is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations[12]. - The company has not undergone an audit for the Q3 2023 report[24]. Investments - The company transferred 51% equity of Anhui Hongtai Biochemical Co., Ltd. to Nanjing Huazhou Pharmaceutical Co., Ltd. during the reporting period[13]. - The registered capital of Nanjing Xinzou Technology Co., Ltd. is 20 million CNY, with Nanjing Huazhou Pharmaceutical holding 49% equity[13]. - The company reported an investment income of ¥2,036,664.88, a recovery from a loss of ¥14,038,636.49 in the same period last year[20].